Not every retailer is suffering in this anemic recovery. Foot Locker (FL) stock is hitting all-time highs thanks to record sales and profits in the latest quarter.
Top 5 Supermarket Stocks To Buy Right Now: Celgene Corp (CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.
Commercial! Stage Products
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.
THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.
ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.
Preclinical and Clinical-Stage Pipeline
The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.
The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).
The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.
At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.
The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.
The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).
Advisors' Opinion:- [By DailyFinance Staff]
Stocks bounced in and out of the plus column before picking a direction on Friday. Unfortunately, the path chosen was down again, though not far. The Dow Jones industrial average (^DJI) extended its losing streak to five days, dropping another 43 points. The Standard & Poor's 500 (^GSPC) fell 5 and the Nasdaq composite (^IXIC) lost 15 points. In all, each of the major averages lost in the neighborhood of a quarter of a percent Friday, and all lost ground for the week. Meanwhile, another once-popular teen retailer took a tumble. Shares of Aeropostale (ARO) tumbled 20 percent after the retailer posted a wider than expected quarterly loss. The stock is now down 60 percent over the past year. But investors were buying some other retailers. Zumiez (ZUMZ), also geared toward teens, rose 2½ percent despite forecasting a loss in the current quarter. A couple of chains geared toward women did well. Ulta Salon (ULTA) gained nearly 6½ percent as earnings topped expectations. Ann (ANN), best known for its Ann Taylor stores, rose 7½ percent. And Coach (COH) gained 2 percent. Other gainers today: Green Mountain (GMCR), maker of Keurig, was up 7 percent, after expanding its deal with Starbucks. Liberty Media (LSTZA) ended its deal to buy those shares of Sirius XM (SIRI) it doesn't already own. Both stocks gained on the news; Liberty up 7 percent, Sirius up 2 percent. And Castlight Health (CSLT) soared nearly 150 percent above its $16 a share IPO price. The company, which helps workers choose healthcare benefits, stands to gain from Obamacare. On the downside: Tesla (TSLA) lost another 3 percent on reports that New York could become the fifth state to block the company from selling direct to consumers. Still, Tesla has a pretty good track record. It's stock has soared more than 500 percent over the past year. Biotechs continued to lose ground. Celgene (CELG) fell 4 percent on a double dose of bad news. British regulators reportedly plan to rejec
- [By John Udovich]
Biotech and the cancer treatment segment of the biotech market has been a hot area for some time with important cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps�Array BioPharma (NASDAQ: ARRY), Cancer Genetics Inc (NASDAQ: CGIX), EXACT Sciences Corporation (NASDAQ: EXAS) and�MetaStat Inc (OTCMKTS: MTST) all producing a steady flow of important news�for investors this week or in recent weeks. Consider the following:
- [By Ben Levisohn]
Shares of Celgene (CELG) are dropping this morning after the biotech giant said that its arthritis drug failed to meet its primary endpoint in a Phase III trial. Bernstein’s Geoffrey Porges and Wen Shi aren’t concerned:
The ankylosing spondylitis indication offered upside compared to our forecasts and estimates for Celgene, but was not part of our base case valuation. This disappointment is likely to have some negative effects on sentiment and the stock, but the overall negative reaction is likely to be modest. Celgene’s stock has performed strongly in recent weeks, partly on the basis, we suspect, of company buying. We remain positive about the stock’s outlook for the next 6-12 months, and also increasingly positive on the early stage pipeline which is likely to show its potential more clearly in the next 18 months.
Celgene’s drop has, in fact, been modest. Its shares have fallen 0.5% to $85.28 at 10:26 a.m., while Amgen (AMGN) has dipped 0.4% to $119.45, Biogen Idec (BIIB) has declined 0.6% to $315.58 and the iShares Nasdaq Biotechnology ETF (IBB) is off 0.6% at $252.28.
- [By Ben Levisohn]
Shares of the United Therapeutics have surged 23% to $107.65, on what’s looking to be a pretty decent day for biotech stocks. The iShares Nasdaq Biotechnology Index ETF (IBB) has gained 0.9% to $225.75, as Gilead Sciences (GILD) has risen 0.7% to $75.16 and Celgene (CELG) has ticked up 0.4% to $168.09.
Hot Warren Buffett Stocks To Watch For 2014: American Capital Agency Corp (AGNC)
American Capital Agency Corp. (AGNC) is a real estate investment trust (REIT). The Company earns income primarily from investing on a leveraged basis in agency mortgage-backed securities. These investments consist of residential mortgage pass-through securities and collateralized mortgage obligations (CMOs) for which the principal and interest payments are guaranteed by government-sponsored entities, such as the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac), or by a United States Government agency, such as the Government National Mortgage Association (Ginnie Mae) (collectively, GSEs). It may also invest in agency debenture securities issued by Freddie Mac, Fannie Mae or the Federal Home Loan Bank (FHLB). The Company is managed by American Capital AGNC Management, LLC, which is an affiliate of American Capital, Ltd.
AGNC funds its investments primarily through short-term borrowings structured as repurchase agreements. The agency mortgage-backed securities in which the Company invests consist of agency residential pass-through certificates and CMOs. Agency residential pass-through certificates are securities representing interests in pools of mortgage loans secured by residential real property. Agency CMOs are securities that are structured instruments representing interests in agency residential pass-through certificates. Agency CMOs consist of multiple classes of securities.
Advisors' Opinion:- [By David Hanson and Matt Koppenheffer]
One of the biggest movers today is Armour Residential REIT (NYSE: ARR ) , falling over 6% at one point. Two mREITs run by Gary Kain, American Capital Agency (NASDAQ: AGNC ) and American Capital Mortgage (NASDAQ: MTGE ) , were also trading lower.
- [By Selena Maranjian]
Finally, Fred Alger Management's biggest closed positions included QLIK Technologies�and Triumph Group. Other closed positions of interest include 3D Systems (NYSE: DDD ) and American Capital Agency (NASDAQ: AGNC ) . Many have high hopes for 3D Systems, but it hasn't been growing organically as quickly as some might like. The company's last earnings report was a bit mixed, with revenue up 31%, and net income dropping. But 3-D printing is still in its infancy, with much promise. Some see the shares as a bit rich now, though, and there has been insider selling. Another concern is that fellow 3D specialist Stratasys�is buying MakerBot�-- though there's a case to be made that the real future of 3D printing is in the commercial arena, not retail. Meanwhile, 3D Systems has been making some acquisitions of its own.
Hot Warren Buffett Stocks To Watch For 2014: Home Properties Inc. (HME)
Home Properties, Inc. is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It is engaged in the ownership, management, acquisition, rehabilitation and development of residential apartment communities. The firm also invests in townhomes and offices. Home Properties, Inc. was founded in November 1993 and is based in Rochester, New York.
Advisors' Opinion:- [By Marc Bastow]
Apartment community real estate investment trust (REIT) Home Properties (HME) raised its quarterly dividend 4.3% to 73 cents per share, payable on Feb. 25 to shareholders of record as of February 13. At a 5% yield, HME is the highest yielder of this week’s list of dividend stocks increasing payouts.
HME Dividend Yield: 5.00%
Hot Warren Buffett Stocks To Watch For 2014: Guidance Software Inc.(GUID)
Guidance Software, Inc. provides digital investigative solutions to government agencies and corporations primarily in the Americas, Europe, the Middle East, Africa, and Asia/the Pacific Rim. It offers EnCase platform for organizations to search, collect, and analyze electronically stored information to address human resources matters, litigation matters, allegations of fraud, suspicious network endpoint activity, and defend their data assets. The company?s EnCase Enterprise software provides visibility into laptops, desktops, and file servers to conduct internal investigations and determine the root cause of suspicious network activity; and EnCase eDiscovery solution to automatically perform search, collection, preservation, and processing of electronically stored information from unstructured and semi-structured data stores. Its EnCase Cybersecurity forensic solution to expose, triage, and remediate threats, and to enforce data policy compliance on endpoints; EnCase Fore nsic computer investigation solution allows examiners to acquire data from various devices and unearth potential evidence, and craft reports on their findings; and EnCase Portable solution allows forensic professionals and non-experts to triage and collect digital evidence forensically. The company also offers hardware products, including write blockers, forensic duplicators, and storage devices; professional services, such as eDiscovery, network security incident response, civil/criminal digital investigation, and implementation services; and packaged services. It serves various industries, such as financial and insurance services, technology, defense contracting, telecom, pharmaceutical, healthcare, manufacturing, and retail. The company sells its software products and services primarily through its direct sales force; and hardware products principally through resellers. Guidance Software, Inc. was founded in 1997 and is headquartered in Pasadena, California.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Guidance Software (Nasdaq: GUID ) , whose recent revenue and earnings are plotted below. - [By Evan Niu, CFA]
What: Shares of Guidance Software (NASDAQ: GUID ) got crushed today -- down by 25% at the low -- after the company reported first-quarter results.
No comments:
Post a Comment